What are the five‑year survival rates for each molecular subgroup (WNT‑activated, SHH‑activated, Group 3, Group 4) of posterior‑fossa medulloblastoma in a 13‑year‑old boy after maximal safe resection followed by standard craniospinal irradiation and chemotherapy?

Five-Year Survival Rates by Molecular Subgroup in Posterior Fossa Medulloblastoma

For a 13-year-old boy with posterior fossa medulloblastoma treated with maximal safe resection followed by standard craniospinal irradiation and chemotherapy, the five-year survival rates differ dramatically by molecular subgroup: WNT-activated tumors have >90% long-term survival, Group 4 tumors show 75-90% overall survival, SHH-activated tumors demonstrate variable outcomes (53-61% depending on TP53 status), and Group 3 tumors have the poorest prognosis at 20-30% five-year survival. 1

Subgroup-Specific Survival Data

WNT-Activated Medulloblastoma

• Long-term survival rates exceed 90% 1
• Most common in children aged 7-14 years (this patient's age group)
• Represents approximately 10% of all medulloblastomas
• Essentially curative with standard therapy in this age group
• Some studies report 100% five-year overall survival in WNT patients 2

SHH-Activated Medulloblastoma

The prognosis varies significantly based on TP53 mutation status:

• TP53 wild-type: Better outcomes, though specific survival rates vary
• TP53 mutant: Very poor outcomes, worse than TP53 mutation alone when combined with MYCN amplification 1
• Overall 5-year progression-free survival of 61.3% in one cohort 3
• Another study showed 53.6% five-year overall survival 2
• Represents 10-20% of medulloblastomas
• Critical caveat: TP53 mutations and MYCN amplification are associated with each other and confer particularly dismal prognosis 1

Group 3 Medulloblastoma

• Five-year survival rates between 20-30% 1
• Represents 25-35% of medulloblastomas
• Poorest prognosis among all subgroups
• However, not all Group 3 patients have uniformly poor outcomes - those without MYC/MYCN amplification fare better 2
• With carboplatin intensification, survival improved to 73.2% in one trial 4
• MYC amplification is a particularly ominous feature

Group 4 Medulloblastoma

• Overall survival rates between 75-90% 1
• Represents 25-35% of medulloblastomas
• Excellent outcomes in irradiated patients over 3 years: 5-year progression-free survival of 95.9% for average-risk and 88.7% across all Group 4 patients in one cohort 3
• Generally more favorable than Group 3, though less favorable than WNT

Critical Risk Modifiers Beyond Molecular Subgroup

The following factors automatically classify patients as high-risk regardless of molecular subgroup and worsen prognosis 1:

• Metastatic disease (M1-M4 staging)
• Subtotal resection (>1.5 cm² residual disease)
• MYC or MYCN amplification
• Large cell/anaplastic histology (though this is subjective and institution-dependent)

Age-Specific Considerations for This 13-Year-Old

At age 13, this patient falls into the optimal age range for:

• WNT tumors (most common ages 7-14 years with best outcomes)
• Standard craniospinal irradiation (age >3 years allows full-dose radiation without the devastating neurocognitive effects seen in younger children)
• Better tolerance of intensive chemotherapy compared to infants

Overall Medulloblastoma Survival Context

Across all molecular subgroups combined, approximately 75% of children with medulloblastoma achieve prolonged survival with modern multimodality therapy 1. However, this aggregate statistic masks the profound differences between molecular subgroups that should guide prognostic discussions and treatment decisions.

Clinical Application Algorithm

For prognostic counseling of this 13-year-old:

1. Obtain molecular subgroup classification (DNA methylation profiling is gold standard) 1
2. Assess TP53 status if SHH subgroup identified
3. Evaluate for MYC/MYCN amplification in all subgroups
4. Confirm extent of resection on postoperative MRI (ideally within 24-48 hours)
5. Stage for metastatic disease with spine MRI and CSF cytology
6. Integrate molecular and clinical factors to provide subgroup-specific survival estimates as outlined above

The molecular subgroup is now the single most important prognostic factor and should be obtained in all cases to guide both treatment intensity and family counseling 1.